Express Mail Label No. EV 019 435 415 US

Date of Deposit: August 27, 2002

09-03-2002

REC

ey Docket No. VPI/00-101 CON US

(R	ORM PTO-1595 lev. 6-93) MB No. 0651-0011 (exp. 4/94)	U.S. DEPARTMENT OF COMMERCE Patent and Trademark Office								
Please record the attached original documents or copy thereof.										
1.	Name of conveying party(ies): a) Paul Charifson; b) Dean Stamos; c) Michael Badia; d) Anne-Laure Grillot; e) Steven Ronkin; and f) Martin Trudeau Additional name(s) of conveying party(ies) attached? Yes No	2. Name and address of receiving party(ies) Name: Vertex Pharmaceuticals, Incorporated Internal Address: Street Address: 130 Waverly Street Cambridge, MA 02138-4242								
3.	Nature of conveyance: ☐ Assignment ☐ Merger ☐ Security Agreement ☐ Change of Name ☐ Other ☐ Execution Date: a)-f) January 17, 2001	Additional name(s) & address(es) attached?								
4.	Application number(s) or patent number(s): If this document is being filed together with a new application, the execution do A. Patent Application No(s): 10/198,407 Additional numbers attack	B. Patent No(s):								
5.	Name and address of party to whom correspondence Concerning document should be mailed: Name: Nandakumar Govindaswamy Address: VERTEX PHARMACEUTICALS INCORPORATED 130 Waverly Street Cambridge, MA 02138-4242	 6. Total number of applications and patents involved: [1] 7. Total fee (37 CFR 3.41) \$40.00 ☐ Enclosed ☑ The Commissioner is authorized to charge Deposit Account No: 50-0725, Reference No. VPI/00-101 CON US. 								
DO NOT USE THIS SPACE										
N	Statement and signature To the best of my knowledge and belief, the foregoing information is true and landakumar Govindaswamy Name of Person Signing Signature Total number of pages including cover sheet, attachments, and document: [9]	August 27, 2002 Date								

Mail documents to be recorded with required cover sheet information to:

BOX ASSIGNMENT Commissioner of Patents and Trademarks Washington, D.C. 20231

08/30/2002 09/30: 100007 15 500725 1009840

BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE UNITED STATE PATENT AND TRADEMARK OFFICE

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Nandakumar Govindaswamy is hereby given limited recognition under 37 CFR §10.9(b) as an employee of Vertex Pharmaceuticals, Inc. to prepare and prosecute patent applications wherein the patent application is assigned to Vertex Pharmaceuticals, Inc., and the attorney or agent of record in the applications is a registered practitioner who is an employee of Vertex Pharmaceuticals, Inc. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Nandakumar Govindaswamy ceases to lawfully reside in the United States, (ii) Nandakumar Govindaswamy's employment with Vertex Pharmaceuticals, Inc. ceases or is terminated, or (iii) Nandakumar Govindaswamy ceases to remain or reside in the United States on an H-1B visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: June 30, 2003

Harry Moatz,

Director of Enrollment and Discipline

PCT ASSIGNMENT

I/We,

- (1) Paul Charifson,
- (2) Dean Stamos,
- (3) Michael Badia,
- (4) Anne-Laure Grillot,
- (5) Steven Ronkin,
- (6) Martin Trudeau

residing, respectively, at

- (1) 7 Dartmouth Drive
 Framingham, Massachusetts, 01701 USA
- (2) <u>28 Londonderry Avenue</u> Framingham, Massachusetts, 01701 USA
- (3) <u>20 Meadowbrook Road</u>
 Bedford Massachusetts, 01730 USA
- (4) 31 Regent Street #3R
 Cambridge, Massachusetts, 02140 USA
- (5) <u>16 Jensen Street</u>
 Watertown, Massachusetts, 02472 USA
- (6) <u>163 Merrimack Meadows</u> Tewksbury, Massachusetts, 01876 USA

for good and valuable consideration, receipt of which is hereby acknowledged, have assigned, sold and transferred to, and do hereby assign, sell and transfer to <u>VERTEX</u>

page 1 of 8

PHARMACEUTICALS INCORPORATED, a corporation organized and existing under the laws of the COMMONWEALTH OF MASSACHUSETTS and having an office and a place of business at 130 WAVERLY STREET, CAMBRIDGE, MASSACHUSETTS 02139-4242, its successors and assigns: (1) the entire right, title and interest in all countries throughout the world in and to any and all my/our inventions and discoveries disclosed in my/our International Patent Application, filed under the Patent Cooperation Treaty in the United States Receiving Office (RO/US), entitled: "GYRASE INHIBITORS AND USES THEREOF" and designating Albania (AL), Algeria (DZ), Antigua & Barbuda (AG), Armenia (AM), Australia (AU), Austria (AT), Azerbaijan (AZ), Barbados (BB), Belarus (BY), Belgium (BE), Benin (BJ), Bosnia and Herzegovina (BA), Brazil (BR), Bulgaria (BG), Burkina Faso (BF), Cameroon (CM), Canada (CA), Central African Republic (CF), Chad (TD), China (CN), Columbia (CO), Congo (CG), Costa Rica (CR), Côte d'Ivoire (CI), Croatia (HR), Cuba (CU), Cyprus (CY), Czech Republic (CZ), Democratic People's Republic of Korea (KP), Denmark (DK), Dominica (DM), Estonia (EE), Finland (FI), France (FR), Gabon (GA), Gambia (GM), Georgia (GE), Germany (DE), Ghana (GH), Greece (GR), Grenada (GD), Guinea (GN), Guinea Bissau (GW), Hungary (HU), Iceland (IS), India (IN), Indonesia (ID), Ireland (IE), Israel (IL), Italy (IT), Japan (JP), Kazakstan (KZ), Kenya (KE), Kyrgyzstan (KG), Latvia (LV), Lesotho (LS), Liberia (LR), Liechtenstein (LI), Lithuania (LT), Luxembourg (LU), Madagascar (MG), former Yugoslav Republic of Macedonia (MK), Malawi (MW), Mali (ML), Mauritania (MR), Mexico (MX), Monaco (MC), Mongolia (MN), Morocco (MA), Mozambique (MZ), Netherlands (NL), New Zealand (NZ), Niger (NE), Norway (NO), Poland (PL), Portugal (PT),

Republic of Korea (KR), Republic of Moldova (MD), Romania (RO), Russian Federation (RU), Saint Lucia (LC), Senegal (SN), Sierra Leone (SL), Singapore (SG), Slovakia (SK), Slovenia (SI), South Africa (ZA), Spain (ES), Sri Lanka (LK), Sudan (SD), Swaziland (SZ), Sweden (SE), Switzerland (CH), Tajikistan (TJ), Tanzania (TZ), Togo (TG), Trinidad and Tobago (TT), Turkey (TR), Turkmenistan (TM), Uganda (UG), Ukraine (UA), United Arab Emirates (AE), United Kingdom (GB), United States of America (US), Uzbekistan (UZ), Viet Nam (VN), Yugoslavia (YU), and Zimbabwe (ZW), [subsequently identified as International Patent Application ______, filed [____*], any renewals, revivals, reissues, including reexaminations, extensions, continuations and divisions thereof, and any substitute applications therefor; (2) the full and complete right to file patent applications in the name of VERTEX PHARMACEUTICALS INCORPORATED, its designee, or in my/our names at VERTEX PHARMACEUTICALS INCORPORATED, or its designee's election, on aforesaid inventions, discoveries and applications in all countries of the world; (3) the entire right, title and interest in and to any Letters Patent which may issue on the aforesaid inventions, discoveries and applications in any country of the world and any renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation, registration and importation of the same; and (4) the entire right, title and interest in and to all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of

page 3 of 8

^{*} I/We hereby authorize <u>VERTEX PHARMACEUTICALS INCORPORATED</u> and its representatives to insert in this instrument the International Patent Application number and the filing date of said application when <u>VERTEX PHARMACEUTICALS INCORPORATED</u> is officially notified thereof.

priority in any country of the world, in and to the following priority application(s):

60/176,671UNITED STATES
countryJanuary 18, 2000application no.countryfiling date60/254,331UNITED STATES
application no.December 8, 2000
filing date

and all rights of priority in any country of the world deriving from the above-identified International Patent Application.

I/We hereby authorize and request the competent authorities to grant and to issue any all such Letters Patent in any country throughout the world to VERTEX
PHARMACEUTICALS INCORPORATED as the assignee of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by me/us had this assignment, sale and transfer not been made.

I/We agree, at any time, upon the request of VERTEX PHARMACEUTICALS INCORPORATED to execute to PHARMACEUTICALS INCORPORATED VERTEX deliver to additional applications for patents for said inventions discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on applications, ordiscoveries inventions, revivals, reissues, divisions, continuations, renewals, reexaminations and extensions thereof.

of <u>VERTEX PHARMACEUTICALS INCORPORATED</u> to execute and to deliver to <u>VERTEX PHARMACEUTICALS INCORPORATED</u> such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of

page <u>4</u> of 8

the world, and otherwise to do the necessary to give full effect to and to perfect any and all rights of <u>VERTEX PHARMACEUTICALS INCORPORATED</u> under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

ASSIGNORS:

•	
Paul Charifson Paul Charifson	(1)
Paul Charif k on	
()	
Pin >	(2)
Dean Stamos	
Michael Bedie	(3)
Michael Badia	
chas kound fatel	(4)
Anne-Laure Grillot	
•	
1 1)	(5)
Steven Ronkin	
1	
1/a di Turdon.	161
Martin Trudeau	(6)
/ Martin Tradeau	
·	

page 5 of 8

	On thi	s /7	day	of _	JANUA	~		2001	- /
Paul	Charifson								
Notary	Public	in	and	for	the	Com	nonwea	lth_	of
Massac	chusetts, a	nd exe	ecuted	the	foregoi	ng A	ssign	ment	and
duly a	acknowledge	d to m	ne that	suc.	h Assigr	ment	was	execu	ted
for th	ne uses and	purpo	ses th	ereir	n expres	sed.			

Notary Public

On this 19^{13} day of $5mu_{40}$, 2001, Dean Stamos (2) personally appeared before me, a Notary Public in and for the Commonwealth of Massachusetts , and executed the foregoing Assignment and duly acknowledged to me that such Assignment was executed for the uses and purposes therein expressed.

Notary Public

On this 17 day of Source , 2001, Michael Badia (3) personally appeared before me, a Notary Public in and for the Commonwealth of Massachusetts, and executed the foregoing Assignment and duly acknowledged to me that such Assignment was executed for the uses and purposes therein expressed.

Notary Public Tolay

page 6 of 8

On this 17 day of Jawuac , 2001, Anne-Laure Grillot (4) personally appeared before me, a Notary Public in and for the Commonwealth of Massachusetts, and executed the foregoing Assignment and duly acknowledged to me that such Assignment was executed for the uses and purposes therein expressed.

Notary Public

On this And day of January, 2001, Steven Ronkin (5) personally appeared before me, a Notary Public in and for the Commonwealth of Massachusetts, and executed the foregoing Assignment and duly acknowledged to me that such Assignment was executed for the uses and purposes therein expressed.

Notary Public

On this 17 day of Jawan, 2001, Martin Trudeau (6) personally appeared before me, a Notary Public in and for the Commonwealth of Massachusetts, and executed the foregoing Assignment and duly acknowledged to me that such Assignment was executed for the uses and purposes therein expressed.

Notary Public

page 7 of 8

ACKNOWLEDGEMENT OF ASSIGNEE:

VERTEX PHARMACEUTICALS INCORPORATED

Bv:

Andrew S. Marks

RECORDED: 08/27/2002

Chief Patent Counsel

On this 17 day of January, 2001, Andrew S. Marks personally appeared before me, a Notary Public in and for the Commonwealth of Massachusetts, and duly acknowledged the executed Assignment on behalf of the Assignee.

Notary Public

page 8 of 8